Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Karyopharm Therapeutics Inc. (KPTI)

3.49   0.17 (5.12%) 03-27 16:00
Open: 3.28 Pre. Close: 3.32
High: 3.55 Low: 3.2507
Volume: 1,680,784 Market Cap: 396(M)

Technical analysis

as of: 2023-03-27 4:20:40 PM
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 4.18     One year: 4.89
Support: Support1: 3.12    Support2: 2.83
Resistance: Resistance1: 3.58    Resistance2: 4.18
Pivot: 3.31
Moving Average: MA(5): 3.34     MA(20): 3.26
MA(100): 3.74     MA(250): 4.77
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 67.7     %D(3): 62.7
RSI: RSI(14): 56.5
52-week: High: 8.63  Low: 2.45
Average Vol(K): 3-Month: 2,684 (K)  10-Days: 2,854 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ KPTI ] has closed below upper band by 27.3%. Bollinger Bands are 36.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 3.56 - 3.57 3.57 - 3.59
Low: 3.21 - 3.23 3.23 - 3.25
Close: 3.46 - 3.49 3.49 - 3.52

Company Description

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Headline News

Mon, 27 Mar 2023
Karyopharm Therapeutics Inc. (KPTI) vs. Its Peers: A Comparison - The News Heater

Mon, 27 Mar 2023
Why Acquire Shares Of Karyopharm Therapeutics Inc. (KPTI)? - Marketing Sentinel

Sun, 26 Mar 2023
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Stock Holdings ... - MarketBeat

Sat, 18 Mar 2023
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Consensus ... - MarketBeat

Mon, 13 Mar 2023
Is Karyopharm Therapeutics Inc (KPTI) a Stock to Watch After Gaining 6.87% This Week? - InvestorsObserver

Thu, 09 Mar 2023
Have Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Insiders Been Selling Their Stock? - Simply Wall St

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 113 (M)
Shares Float 72 (M)
% Held by Insiders 6.2 (%)
% Held by Institutions 72.6 (%)
Shares Short 23,140 (K)
Shares Short P.Month 20,910 (K)

Stock Financials

EPS -2.73
EPS Est Next Qtl -0.62
EPS Est This Year -2.62
EPS Est Next Year -2.31
Book Value (p.s.) -0.53
Profit Margin (%) -35.3
Operating Margin (%) -20.7
Return on Assets (ttm) -13.3
Return on Equity (ttm) 0
Qtrly Rev. Growth -4.1
Gross Profit (p.s.) 0.5
Sales Per Share 2.2
EBITDA (p.s.) -0.45
Qtrly Earnings Growth 0
Operating Cash Flow -97 (M)
Levered Free Cash Flow -56 (M)

Stock Valuations

PE Ratio -1.29
PEG Ratio 0
Price to Book value -6.59
Price to Sales 1.58
Price to Cash Flow -4.07

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.